This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Accuray Gains on Radixact Unit, Solid Geographical Foothold
by Zacks Equity Research
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
by Zacks Equity Research
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
by Zacks Equity Research
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
by Zacks Equity Research
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
by Zacks Equity Research
Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
by Zacks Equity Research
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
Stryker (SYK) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.
Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
Varian Gains Ground on New Applications, Grows in Australia
by Zacks Equity Research
Varian's (VAR) innovative product pipeline will continue to drive growth over the long term.